Skip to main content
EYSUVIS® (loteprednol etabonate ophthalmic suspension) home page

For the scratching, burning, and redness of a dry eye flare-up

Meet the only drop that’s
there for the flare

The only FDA‑approved short‑term prescription eye drop that quickly* treats at the source of dry eye symptom flare‑ups.

Learn About Eysuvis

Take a short quiz to see what can be done
about your dry eye symptom flare‑ups .

The EYSUVIS ‘I SAVE’ Program may be able to help you pay less for your prescription.

SEE HOW YOU CAN SAVE

EYSUVIS® (loteprednol etabonate ophthalmic suspension) savings card

Contact us

For additional information or to report an adverse event, call Kala Pharmaceuticals, Inc. at 1‑833‑287‑KALA
(1‑833‑287‑5252).

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit , or call 1‑800‑FDA‑1088.

Sign up for updates

Want to know more about EYSUVIS? Register your email to get updates and information on the drop that’s there for the flare.

* In a clinical trial program with 2871 patients with dry eye, patients using EYSUVIS showed significant reduction in the symptoms of dry eye (ocular discomfort) as early as Day 4 after starting treatment (versus placebo). Symptoms continued to improve up to the end of the treatment period (Day 15). Patients taking EYSUVIS also showed significant reduction in signs of dry eye (eye redness) at Day 15 versus placebo.